Prevention of Postoperative Blood Loss: Randomised Unicentric Parallel Clinical Trial That Assess the Efficacy of Fibrin Glue and Tranexamic Acid in Surgical Patients With a Total Knee Arthroplasty.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 172
- 试验地点
- 1
- 主要终点
- Postoperative blood loss (mL)
研究概览
简要总结
Objectives:
a) Principal: To assess if the fibrin glue or the tranexamic acid reduce less than 20% the blood losses with respect to the habitual haemostasia in patients with arthroplasty total of knee.
Secondaries: To assess the treatment safety. To perform a cost- analyses.
Methods: Randomized, unicentric, and parallel clinical trial with four comparative groups: Tissucol® (fibrin glue), fibrin glue manufactured by the Cryoseal® system (Banc de Sang i Teixits de Catalunya), tranexamic acid and habitual haemostasia.
Nº of participant centres: 1. Random allocation will be centralised.
Main outcome: Blood losses (ml) in the post-operatory period collected by the habitual drain system.
Secondary outcomes: Proportion of patients with blood transfusion, complications of surgery wound, pre and post-operative haemoglobin, units of blood transfused, post-operative mortality, days of hospital stay, safety of interventions assessed.
Size sample calculation: The number needed of patients is 172 (43 per group) to demonstrate a 20% difference in the post-operative blood losses between the treatments assessed and the habitual haemostasia, with a statistical power of 80% and a 0.05 bilateral alpha, and a 20% of withdrawals.
Statistical analysis: The investigators will perform a comparison of outcomes through the "t" test, the Mann-Whitney test of chi square, depending of the evaluated outcomes, quantitative or ordinals or qualitative, respectively. The software used will be Statistical Package for the Social Sciences (SPSS) version 17.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Total knee arthroplasty
- •The patient consent to participate
排除标准
- •Intolerance drugs to the study or to bovine protein (aprotinin)
- •Antecedent of thromboembolic disease
- •Patient with cardiac alterations of the rhythm
- •Patients with valvular cardiac prosthesis
- •Patients with pro-thrombotic alterations of coagulation
- •Treatment with anticonceptive drugs
研究组 & 干预措施
Tranexamic acid
Tranexamic acid is a synthetic derivative of the amino acid lysine. It inhibits fibrinolysis by blocking the lysine binding sites on plasminogen and facilitates the coagulation process.
干预措施: Tranexamic Acid (Drug)
Fibrin glue BSTC
It is homologous fibrin glue from a single blood donor.
干预措施: Fibrin glue (Biological)
Tissucol
It is fibrin glue commercialized from multiple donors.
干预措施: Fibrin glue (Biological)
Habitual haemostasis
Electrocoagulation of blood vessels was performed during surgery in all patients (routine hemostasis)
干预措施: Habitual haemostasis (Other)
结局指标
主要结局
Postoperative blood loss (mL)
时间窗: During the first 48h after the surgical intervention
Blood loss (mL) by the surgical wound collected by drain systems.
次要结局
- Percentage of patients that need a postoperative blood transfusion(During the first postoperative week)
- Percentage of patients with surgical wound infection(During the first postoperative month)
- Percentage of patients with surgical wound dehiscence(During the first postoperative month)
- Percentage of patients with re-intervention by wound complications(During the first postoperative month)
- Incidence of deep venous thrombosis(During the first postoperative week)
- Pain of surgical wound(During the first postoperative week)
- Units of blood transfusion(During the first postoperative week)
- hospital length stay(Days)
- Mortality(During the first postoperative month)
